Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Calisu for neonatal acute respiratory distress syndrome
ChiCTR2200057537Phase 4Not yet recruiting
- Sponsor
- Jinan Children's Hospital
- Start
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Poractant alfa in acute respiratory distress syndrome (ARDS), sponsored by Jinan Children's Hospital. Primary endpoint: Number of deaths. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
Poractant alfa
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2200057537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057537.